批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2023/02/24 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2022/02/11 |
SUPPL-15(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2019/07/31 |
SUPPL-12(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2017/01/11 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2017/01/11 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2016/06/08 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2015/09/24 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
;Orphan
|
|
|
2014/10/15 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
;Orphan
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:PIRFENIDONE 剂型/给药途径:CAPSULE;ORAL 规格:267MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
022535 |
001 |
NDA |
ESBRIET |
PIRFENIDONE |
CAPSULE;ORAL |
267MG |
Prescription |
Yes |
Yes |
AB |
2014/10/15
|
GENENTECH INC |
212569 |
001 |
ANDA |
PIRFENIDONE |
PIRFENIDONE |
CAPSULE;ORAL |
267MG |
Prescription |
No |
No |
AB |
2022/01/03
|
AMNEAL |
212731 |
001 |
ANDA |
PIRFENIDONE |
PIRFENIDONE |
CAPSULE;ORAL |
267MG |
Prescription |
No |
No |
AB |
2022/01/20
|
ACCORD HLTHCARE |
212600 |
001 |
ANDA |
PIRFENIDONE |
PIRFENIDONE |
CAPSULE;ORAL |
267MG |
Prescription |
No |
No |
AB |
2022/06/13
|
SANDOZ |
212724 |
001 |
ANDA |
PIRFENIDONE |
PIRFENIDONE |
CAPSULE;ORAL |
267MG |
Prescription |
No |
No |
AB |
2022/07/19
|
LAURUS |
212077 |
001 |
ANDA |
PIRFENIDONE |
PIRFENIDONE |
CAPSULE;ORAL |
267MG |
Prescription |
No |
No |
AB |
2022/08/01
|
SCIEGEN PHARMS INC |
212687 |
001 |
ANDA |
PIRFENIDONE |
PIRFENIDONE |
CAPSULE;ORAL |
267MG |
Discontinued |
No |
No |
AB |
2023/06/09
|
APOTEX |
212404 |
001 |
ANDA |
PIRFENIDONE |
PIRFENIDONE |
CAPSULE;ORAL |
267MG |
Discontinued |
No |
No |
AB |
2023/08/28
|
CHARTWELL RX |